LEVOFLOXACIN 500mg. IP

A broad-spectrum, bactericidal antibiotic of the fluoroquinolone drug class that treats bacterial infections. (Podder & Sadiq, 2020) A valuable antimicrobial agent that has high levels of susceptibility among Gram-negative, Gram-positive including penicillin-resistant strains of Streptococcus pneumonia and atypical pathogens. (Antoni Torres, 2012) More active against gram-positive pathogens than ciprofloxacin. (Miriam Hurst, 2002) As effective as gatifloxacin, clarithromycin, azithromycin or amoxicillin/clavulanic acid in patients with mild to severe community-acquired pneumonia. (Miriam Hurst H. M., 2002) An effective therapy as intravenous imipenem/cilastatin in suspected bacteraemia patients. (Miriam Hurst H. M., 2002) A therapeutic regimen in patients with uncomplicated skin and skin structure infections, and complicated urinary tract infections. (Miriam Hurst H. M., 2002) Achieves 64.7% clinical success rate as compared with 41.2% with comparator treatment (imipenem/cilastatin followed by ciprofloxacin) in patients diagnosed with nosocomial pneumonia. (Alan M Tennenberg, 2006) Exhibits good clinical and microbiological efficacy for use in lower respiratory tract infections that are caused by Streptococcus pneumoniae. (Guoying Cao, 2020) Demonstrates antibacterial efficacy against a variety of infections, including upper and lower respiratory tract, genitourinary, obstetric, gynecological, and skin and soft tissues. (R Davis, 1994) An attractive option for the treatment of at-risk patients with serious respiratory tract infections including community-acquired pneumonia and acute exacerbations of chronic bronchitis. (Rafael Cantón, 2006)